Drugs / BPX-501 T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03459170 | Feb 2018 → Sep 2022 overdue | hematopoietic and lymphoid cell neoplasm | Bellicum Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03301168 | Apr 2014 → May 2021 overdue | acute lymphoblastic leukemia, aplastic anemia, childhood acute myeloid leukemia, hemoglobinopathy +3 | Bellicum Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPX-501 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03459170 ↗ |
| Modality | Cell therapy | “T cells transduced with CaspaCIDe® safety switch” NCT03301168 ↗ |